Physician profile
Mark Evan Reeves
NPI 1467482554
$11,220.65
in general payments reported to CMS, 2019-2025
9 companies · $10K in 2025
The $10K reported for 2025 was more than what 93% of Surgical Oncology providers received nationally (typical 2025 total: $288).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $85.93 · 2022: $267 · 2024: $369 · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $7,818 · Travel and Lodging: $1,945 · Food and Beverage: $1,104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $7,818.49 |
| Travel and Lodging | $1,944.82 |
| Food and Beverage | $1,104.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $9,080.45 | 2025 | |
| Histosonics, INC. | $1,211.60 | 2025 | |
| W. L. Gore & Associates, INC. | $215.32 | 2024 | Excluder Conformable Aaa Endoprosthesis With Active Control |
| Bolton Medical INC | $153.80 | 2024 | Relay Thoracic Stent-Graft With Plus Delivery System |
| Shockwave Medical, INC | $141.26 | 2022 | |
| Caris Mpi, INC. | $137.94 | 2025 | Mi Cancer Seek |
| Angiodynamics, INC. | $125.86 | 2022 | |
| Ethicon US, LLC | $85.93 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $68.49 | 2025 | Imfinzi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Reeves listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.